Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Xenophon Kassianides BSc (Hons), MBBS, MRCP(UK), Sunil Bhandari MBChB, MRCP, FRCP, PhD, M Clin Edu, FHEA

Article Type

Review

Published

This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.